Towards Healthcare
Cell and Gene Therapy (CGT) Pharmaceuticals Market to Grow at 18.93% CAGR till...

Cell and Gene Therapy (CGT) Pharmaceuticals Market Expands with AI Boost

Market insights predict, the cell and gene therapy (CGT) pharmaceuticals industry is expected to grow from USD 16.75 billion in 2024 to USD 91.56 billion by 2034, driven by a CAGR of 18.93%. The growing demand for personalized medicine, driving patient-specific therapies, is estimated to drive the growth of the market. North America led the global market owing to a strong clinical trial landscape, as the U.S. hosts the majority of global trials in cell and gene therapy.

Content

  • Insight Code: 6099
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The cell and gene therapy (CGT) pharmaceuticals market holds a valuation of USD 19.91 billion as of 2025, and will expand to USD 91.56 billion by 2034, achieving a CAGR of 18.93% between 2024 and 2034.

North America is leading the cell and gene therapy (CGT) pharmaceuticals market due to the growing demand for personalized medicines, increasing regulatory approvals, and the presence of key players.

Some key players include Novartis, Gilead Sciences / Kite Pharma, Bristol Myers Squibb (BMS) / Juno Therapeutics, Roche / Spark Therapeutics, bluebird bio, Sarepta Therapeutics, REGENXBIO, and uniQure.

Key trends include the adoption of inorganic growth strategies, funding, and investment.

ASGCT - American Society of Gene & Cell Therapy, Personalized Medicine Coalition, Government of Canada, Cell & Gene Therapy International (CGT), Food and Drug Administration, Indian American Association for Professionals in Cell and Gene Therapy (IAAP-CGT), clinicaltrials.gov, GOV.UK
Any Questions